The aim of this study was to determine the current adverse effects of anti-tuberculosis therapy in children with active tuberculosis from a Reference Center of tuberculosis in Sao Paulo, Brazil.
A retrospective study of cohorts was performed from January of 1990 to December 2006. A total of 287 patients with active tuberculosis, that initially received standard anti-tuberculosis therapy, were included in this study. Incidence of side effects related to therapy was evaluated from patient's medical records. All the information, regarding age, sex, weigh, dose plus duration of anti TB-drug prescribed, associated diseases and medications, severity of side effects and clinical forms of tuberculosis, were obtained.
Of the 153 patients, under any tuberculosis tratment, 53 (34.6%) were male. The distribution by age was as follow: 0–4 years (50%); 5–9 years (24%) and 10–13 (26%). The site of disease was predominantly pulmonary tuberculosis (213 of 287; 76%), and less frequent was TB-extrapulmonary (58 of 287; 24%). Of the 287 patient analyzed, 34 (12%) presented any kind of side effects. All patients developed side effects within the first 60 days of treatment, and none of them have reported any serious adverse reactions. One patient had medication discontinued by rash. Adverse effects were observed in patients over 9 years old, 53% (17 cases). Male patients presented better outcome of symptoms (19/59%), and 13 (41%) female patients present side effects. Also two patients presented hepatics transaminases more than three times the upper limit of normal without drug discontinuation.
In this study the occurrence of side effects was infrequent in children. Association with other pathologies did not increase the incidence of symptoms.
Antituberculosis drugs may determine adverse effects which incidence and severity are variable. These drugs have hepatotoxicity potential and may compromise the treatment regimens, or even can led significant morbidity.
Vera Lucia Amorim, No Financial Disclosure Information; No Product/Research Disclosure Information